Benzinga's M&A Chatter for Thursday April 28, 2016

The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday April 28, 2016:

:

NBCUniversal, a division of Comcast Corporation

announced Thursday, the acquisition of DreamWorks Animation

for approximately $3.8 billion or $41 per share in cash. The transaction is expected to close by the end of 2016, subject to antitrust approvals. DreamWorks closed at $39.95 on Thursday, up 24.07%.

:

Abbott

and St. Jude Medical, Inc.

announced Thursday, an agreement, under which Abbott will acquire St. Jude for $46.75 in cash and 0.8708 shares of Abbott common stock. The total consideration is approximately $85 per share. The transaction is expected to close in Q4 of 2016. St. Jude Medical closed at $77.79 on Thursday, up 25.57%.

:

Sanofi

announced Thursday, that it sent a letter to Medivation, Inc.,

, with a non-binding proposal to acquire Medivation for $52.50 per share in cash. The offer is not contingent on any financing condition. Medivation confirmed it received the unsolicited, non-binding proposal from Sanofi and said it expects to complete its review of the proposal at a scheduled meeting on Thursday. Medivation closed at $56.17 on Thursday, up 7.92%.

:

Qlik Technologies Inc.

is said to have received preliminary offers from private equity firms Thoma Bravo, Bain Capital and Permira, while Vista Capital Partners is considering an offer, according to sources as reported by

on Thursday. The sources said Qlik is working with Morgan Stanley to find potential buyers. Spokespersons for Qlik, Thoma Bravo, Bain and Permira declined comment on the report. Qlik Technologies closed at $29.88 on Thursday, up 3.25%.

:

AbbVie

announced Thursday, that it will acquire Stemcentrx for approximately $5.8 billion in cash and stock. Approximately $2.0 billion of the transaction value will be paid in cash, with the balance in stock. Stemcentrx investors are eligible to receive up to $4 billion in cash, based on milestone payments for the achievement of certain regulatory and clinical developments. The transaction is expected to close in Q2 of 2016. AbbVie closed at $61.20 on Thursday, up $0.50.